In8bio 在《免疫学前沿》上发表了针对胶质母细胞瘤的新型 γ-δ T 细胞治疗方法。 In8bio publishes novel gamma-delta T cell therapy approach for glioblastoma in Frontiers in Immunology.

In8bio 是一家临床阶段的生物制药公司，宣布在《免疫学前沿》上发表一篇文章，讨论他们针对胶质母细胞瘤（一种侵袭性脑癌）的新型 γ-δ T 细胞治疗方法。 In8bio, a clinical-stage biopharmaceutical company, has announced a publication in Frontiers in Immunology that discusses their novel gamma-delta T cell therapy approach for glioblastoma, an aggressive form of brain cancer. 虽然细胞疗法在血液系统恶性肿瘤中显示出希望，但由于肿瘤快速生长和抗原异质性等因素，当应用于 GBM 等实体瘤时，它们面临着挑战。 While cellular therapies have shown promise in hematologic malignancies, they have faced challenges when applied to solid tumors like GBM due to factors such as rapid tumor growth and antigen heterogeneity. 该出版物回顾了 IN8bio 治疗实体瘤的创新策略。 The publication reviews IN8bio's innovative strategy for treating solid tumors.